Company To Launch Stem Cell Exosome Trial In Dystrophic Epidermolysis Bullosa.
BOSTON, Mass., January 7, 2020 -- Aegle Therapeutics Corp., said it has closed a $4M financing round that will be used to fund a clinical trial in dystrophic epidermolysis bullosa (DEB), a rare pediatric skin blistering disorder, in the first half of 2020.
Aegle's technology is based on the research of Evangelos Badiavas, Aegle's founder, who developed a process that safely and efficiently isolates extracellular vesicles (EVs) secreted by allogeneic bone marrow derived mesenchymal stem cells.
In preclinical research, Aegle's EVs demonstrated similar regenerative functionality to their parent cells, opening up the potential for "cell-free" therapy.
Additionally, Aegle's EVs carry specific proteins and mRNA that may prove essential for the treatment of DEB.
Aegle's technology is a platform technology with many potential indications in and beyond dermatology.
Aegle's IND for the treatment of DEB patients has been cleared by the FDA.
The investment was led by Boca Raton, Fla.-based New World Angels, with participation from Tellus BioVentures, DEFTA Healthcare Technologies and DeepWork Capital, as well as OceanAzul Partners, LLC.
Privately-held Aegle Therapeutics is developing a therapy using extracellular vesicles (EVs), including exosomes, secreted by allogeneic bone marrow derived mesenchymal stem cells.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Clinical TRIALS|
|Publication:||Stem Cell Research News|
|Date:||Jan 27, 2020|
|Previous Article:||NYSCF Partners With Company To Develop iPSC-Derived CAR NK Therapeutics.|
|Next Article:||Positive One-Year Data From MultiStem ARDS Study.|